Med Alliance has announced completion on schedule of patient enrolment in the First-in-Man (FIM) study of SELUTION™, a novel sirolimus-coated balloon.
Founded in 2008, Med Alliance is a privately-owned medical technology company based in Switzerland, with an R&D facility in Irvine, California. The company specializes in the development and commercialisation of drug-eluting stents, balloons, polymers and drugs for use in the treatment of coronary and peripheral artery disease.
The SELUTION drug coated balloon (DCB) contains what the company calls “micro-reservoirs” made out of a biodegradable polymer, intermixed with sirolimus. The micro-reservoirs, which are unique to the SELUTION DCB, provide controlled and sustained release of the antirestenotic drug sirolimus, which is expected to provide a therapeutic effect in treating lesions over a prolonged period of time. This new study is intended to demonstrate that SELUTION is the first DCB with sustained release of sirolimus to be effective in the treatment of both superficial femoral artery and popliteal artery lesions.
The objective of the FIM study is to assess the safety and efficacy of SELUTION in the treatment of lesions of the superficial femoral artery and/or the popliteal arteries, assessed at multiple time points through clinical, duplex ultrasound and/or angiographic assessment (six-month time point only). The SELUTION FIM Study is a prospective, controlled, multi-centre, open, single-arm clinical investigation. The primary endpoint of the study is angiographic Late Lumen Loss at six months. Secondary endpoints include Major Adverse Events, Primary Patency, and angiographic Binary Restenosis.
50 patients have been enrolled between 26 October 2016 and 23 May 2017 across four German centres: Franziskus Krankenhaus, Berlin; Evangelisches Krankenhaus Hubertus, Berlin; Vivantes Klinikum Neukölln, Berlin; and Universitäts-Herzzentrum, Bad Krozingen.
Primary endpoint results for the SELUTION FIM study are anticipated later this year, and will complete the documentation required to submit for award of a CE Mark for the SELUTION sirolimus-coated balloon.
“In pre-clinical studies, this technology has demonstrated sustained sirolimus release for several months. These findings gave us the confidence to initiate the FIM, whose results will permit comparison to previous studies of paclitaxel drug-coated balloons in the superficial femoral artery”, commented Principal Investigator Professor Thomas Zeller, Universitaets-Herzzentrum, Bad Krozingen, Germany.
“We are very excited to have completed patient enrolment in this important trial”, added Professor Klaus Brechtel, Franziskus Krankenhaus, Berlin, Germany. “Both I and my co-investigators participating in this study will now be working towards achieving a meaningful result”.
“This FIM will pave the way for studies in other indications, such as Below-the-Knee (BTK) lesions, where a balloon coated with sirolimus may be safer and more effective than one coated with paclitaxel”, concluded Professor Zeller.
“We are delighted to have successfully completed enrolment for this FIM study on schedule”, said Med Alliance Chairman Jeffrey B. Jump. “This represents a significant milestone for the company”.
Source: Med Alliance